Population pharmacokinetic and exposure-response analyses for efficacy and safety of risankizumab in subjects with active Crohn's disease

被引：0
|
作者：
Suleiman, A. [1 ]
Goebel, A. [1 ]
Bhatnagar, S. [2 ]
D'Cunha, R. [2 ]
Liu, W. [2 ]
Pang, Y. [2 ]
机构：
[1] Clin Pharmacol & Pharmacometr, AbbVie, Ludwigshafen, Germany
[2] Clin Pharmacol & Pharmacometr, AbbVie, N Chicago, IL USA
来源：
JOURNAL OF CROHNS & COLITIS | 2022年 / 16卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P574
引用
收藏
页码：I514 / I516
页数：4
相关论文
共 50 条
  • [41] Population Pharmacokinetic and Exposure-Response Analyses of Baloxavir Marboxil in Adults and Adolescents Including Patients With Influenza
    Koshimichi, Hiroki
    Tsuda, Yoshiyuki
    Ishibashi, Toru
    Wajima, Toshihiro
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2019, 108 (05) : 1896 - 1904
  • [42] Population pharmacokinetic and exposure-response analyses of pemigatinib in patients with advanced solid tumors including cholangiocarcinoma
    Gong, Xiaohua
    Akil, Ayman
    Ndi, Andre
    Ji, Tao
    Liu, Xiang
    Lovern, Mark
    Chen, Xuejun
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (11): : 1784 - 1794
  • [43] Development of a Population Pharmacokinetic Model for Binimetinib with Subsequent Exposure-Response Analyses in NRAS Mutant Melanoma
    Wollenberg, Lance
    Marchand, Mathilde
    Merdjan, Henri
    Litwiler, Kevin
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S69 - S69
  • [44] Population pharmacokinetic and exposure-response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia
    Gibiansky, Ekaterina
    Gibiansky, Leonid
    Chavanne, Clarisse
    Frey, Nicolas
    Jamois, Candice
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (08): : 914 - 927
  • [45] Population Pharmacokinetics, Efficacy Exposure-Response Analysis
    Chan, Phyllis
    Yu, Jiajie
    Chinn, Leslie
    Prohn, Marita
    Huisman, Jan
    Matzuka, Brett
    Hanley, William
    Tuckwell, Katie
    Quartino, Angelica
    PHARMACEUTICAL RESEARCH, 2020, 37 (02)
  • [46] Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors
    Mercier, Francois
    Djebli, Nassim
    Gonzalez-Sales, Mario
    Jaminion, Felix
    Meneses-Lorente, Georgina
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (03) : 363 - 372
  • [47] Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients
    Zhou, Diansong
    Li, Jianguo
    Learoyd, Maria
    Bui, Khanh
    Berges, Alienor
    Milenkova, Tsveta
    Al-Huniti, Nidal
    Tomkinson, Helen
    Xu, Hongmei
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2019, 105 (06) : 1492 - 1500
  • [48] Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn's Disease: Analyses of Phase I and II Trials
    Suleiman, Ahmed A.
    Khatri, Amit
    Minocha, Mukul
    Othman, Ahmed A.
    CLINICAL PHARMACOKINETICS, 2019, 58 (03) : 375 - 387
  • [49] Exposure-response analyses of sacituzumab govitecan efficacy and safety in patients with metastatic breast cancer
    Singh, Indrajeet
    Sathe, Abhishek
    Diderichsen, Paul
    Witjes, Han
    Van Schanke, Arne
    Maringwa, John
    Verret, Wendy
    Girish, Sandhya
    Othman, Ahmed
    CANCER RESEARCH, 2024, 84 (09)
  • [50] EXPOSURE-RESPONSE ANALYSES OF UPADACITINIB EFFICACY AND SAFETY IN RHEUMATOID ARTHRITIS - ANALYSES OF PHASE 2 AND 3 STUDIES
    Mohamed, Mohamed-Eslam
    Nader, Ahmed
    Winzenborg, Insa
    Doelger, Eva
    Noertersheuser, Peter
    Pangan, Aileen
    Othman, Ahmed
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 739 - 740
12345